You can track monthly.
But yes in general as I, and others, who like the co have expressed, there is a continuing bleed of shares.
The issues is not even so much about shares alone… the key is growing exponentially faster than the bleed (all growth stocks need to issue to cover growth prior to self funding from ops).
No buzz or visibility in markets or retail that any report here , and no serious ‘for investor’ communications from co. By that I mean presenting the growth plan relative to shares… a case FOR investors.
So while at current price appears undervalued it is hard to see big sustained upside until real visibility from mgt for investors